Introduction: Type 2 diabetes is a common chronic disease that continues to globally increase in prevalence and is a major healthcare burden. Diabetes and hypertension are frequently coexistent conditions and the use of antihypertensive agents is common in diabetic patients. One antihypertensive agent, verapamil, had tentatively shown potentially positive effects on glycaemic control in assorted pre-clinical models. Aim: To evaluate the effect of verapamil on glycaemic control in hypertensive type 2 diabetic patients. Method: Type 2 diabetic hypertensive subjects were recruited from King Fahad Medical City, Riyadh, KSA to receive oral verapamil therapy. Blood pressure and glucometabolic parameters including fasting plasma glucose (FPG), glycated haemoglobin (HbA1c), C-peptide, and Homeostatic Model Assessment Insulin Resistance (HOMA-IR) were monitored at baseline and after 6 months of verapamil therapy. Results: 35 patients (16 male, 19 female) with a mean age of 57.2 years wererecruited. The use of verapamil was associated with non-significant decreases in HbA1c (0.2 ± 1.0%, P=0.25%), FPG (0.5 ± 1.8 mmol/L, P=0.11), C-peptide (0.1 ± 0.3 nmol/L, P=0.06), and HOMA-IR (0.3 ± 0.9, P=0.05).. However a sub-group of 17 participants had a decrease in HbA1c that was ≥ 0.5%. Univariable logistic regression showed that baseline BMI, HOMA-IR, and C-peptide (P
| Date of Award | 7 Oct 2022 |
|---|
| Original language | English |
|---|
| Awarding Institution | - University Of Strathclyde
|
|---|
| Sponsors | University of Strathclyde |
|---|
| Supervisor | Alexander Mullen (Supervisor) & Gazala Akram (Supervisor) |
|---|